Belgium Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Belgium Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Belgium Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View : Belgium offers a stable pharmaceutical market with high per capita spe nding on medicines. However, drugmakers will increasingly find the government less willing to reimburse expensive, innovative medicines as it struggles to hit its fiscal targets.

Headline Expenditure Projections

  • Pharmaceuticals: From EUR5.84bn (USD6.47bn) in 2015 to EUR5.89bn (USD6.30bn) in 2016; +0.9% in local currency terms and -2.6% in US dollar terms.

  • Healthcare: From EUR44.96bn (USD49.87bn) in 2015 to EUR46.13bn (USD49.36bn) 2016; +2.6% in local currency terms and -1.0% in US dollar terms.

Headline Pharmaceuticals & Healthcare Forecasts (Belgium 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 7.730 6.473 6.304 6.565 6.971 7.399 7.540
Pharmaceutical sales, % of GDP 1.45 1.42 1.39 1.36 1.34 1.32 1.30
Pharmaceutical sales, % of health expenditure 13.3 13.0 12.8 12.6 12.5 12.3 12.2
Health spending, USDbn 58.187 49.869 49.356 52.093 55.946 60.018 61.737

Risk/Reward Index

In BMI's Q316 Western European Risk/Reward Index, Belgium scores 73.6 out of 100, placing the country fourth out of the 15 markets in the region, a drop of one place from its position last quarter. Belgium performs well in the Rewards category on account of its high per capita drug consumption, but is closer to the regional average in terms of Risk due to its high levels of government bureaucracy.

Latest Updates

  • In April 2016, Intrexon formed Intrexon T1D Partners, a joint venture with a select group of external investors led by White Rock Capital Partners, to develop ActoBiotics based antigen-specific immunotherapy to treat Type I diabetes in humans. The objective of the programme is to create an easy-to-take tablet for Type I diabetes patients to halt autoimmune-induced damage, both for early- and late-stage patients, to reduce the likelihood of insulin dependence.

  • In April 2016, Zambon and its partner Newron Pharmaceuticals have launched Xadago (safinamide) in Belgium for the treatment of mid- to late-stage Parkinson's disease (PD). Following the launch in Switzerland, Germany, Spain and Italy, Xadago is now available in Belgium as add-on therapy to a stable dose of levodopa alone or in combination with other PD therapies for mid- to late-stage fluctuating patients.

BMI Economic View

Belgian real GDP growth will remain below eurozone averages in 2016 and 2017, as structural labour market reforms drag on private consumption. These same reforms are necessary and should eventually boost longer-term growth. Against this backdrop, we have downgraded our forecasts for real GDP growth to 1.4% in both 2016 and 2017, from a 1.6% forecast previously for both years.

BMI Political View

The Belgian government will struggle to develop adequate responses to elevated security threats, rising Flemish nationalism and the threat of another economic downturn given the country's dire fiscal dynamic. Reflecting this, Brussels was the target of multiple terrorist attacks on March 22, which killed over 35 and injured over 300. The fight against extremism will be one of the key policy challenges for Belgian governments over the next few years.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Belgium 2014-2020)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Belgium 2012-2020)
13
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2012-2020)
16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2012-2020)
16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2012-2020)
16
Prescription Drug Market Forecast
17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Belgium 2012-2020)
18
Patented Drug Market Forecast
19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Belgium 2012-2020)
21
Generc Drug Market Forecast
22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Belgium 2012-2020)
24
OTC Medicine Market Forecast
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Belgium 2012-2020)
26
Pharmaceutical Trade Forecast
27
Table: Pharmaceutical Trade Data And Forecasts (Belgium 2014-2020)
28
Table: Pharmaceutical Trade Data And Forecasts local currency (Belgium 2014-2020)
29
Industry Risk/Reward Index
30
Western Europe Risk/Reward Index
30
Belgium Risk/Reward Index
35
Rewards
35
Risks
35
Regulatory Review
37
Intellectual Property Issues
39
Pricing Regime
39
Reimbursement Regime
41
Table: Reimbursements by Category, 2009
43
Table: Price Build-Up for OTC Medicines
45
Market Overview
46
Healthcare Sector
46
Table: Healthcare Resources (Belgium 2010-2015)
48
Table: Healthcare Personnel (Belgium 2010-2015)
48
Table: Healthcare Activity (Belgium 2010-2015)
49
Research & Development
50
Clinical Trials
51
Epidemiology
52
Competitive Landscape
55
Research-Based Industry
55
Table: Multinational Market Activity
56
Pharmaceutical Distribution
58
Pharmaceutical Retail Sector
58
Company Profile
60
Galapagos
60
Janssen Pharmaceutica
64
UCB Pharma
67
Demographic Forecast
71
Table: Population Headline Indicators (Belgium 1990-2025)
72
Table: Key Population Ratios (Belgium 1990-2025)
72
Table: Urban/Rural Population & Life Expectancy (Belgium 1990-2025)
73
Table: Population By Age Group (Belgium 1990-2025)
73
Table: Population By Age Group % (Belgium 1990-2025)
74
Glossary
76
Methodology
78
Pharmaceutical Expenditure Forecast Model
78
Healthcare Expenditure Forecast Model
78
Notes On Methodology
79
Risk/Reward Index Methodology
80
Index Overview
81
Table: Pharmaceutical Risk/Reward Index Indicators
81
Indicator Weightings
82

The Belgium Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Belgium Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Belgium pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Belgium, to test other views - a key input for successful budgeting and strategic business planning in the Belgian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Belgian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Belgium.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.